menu
    • menu
    [{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baxter Healthcare Corporation \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Biocon"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Norepinephrine Bitartrate","moa":"||Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Baxter Healthcare Corporation

    Menu

    Baxter Healthcare Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norepinephrine Bitartrate,Dextrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

                            Details : Norepinephrine Bitartrate is an adrenergic receptor agonist, small molecule drug candidate. Along with Dextrose it is indicated for the treatment of severe, acute hypotension.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            November 04, 2024

                            Lead Product(s) : Norepinephrine Bitartrate,Dextrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Baxter Secures FDA Approval for Clinolipid in Neonates and Pediatrics

                            Details : Clinolipid is a mixed oil lipid emulsion providing essential fatty acids and calories in parenteral nutrition when oral or enteral nutrition isn’t viable.

                            Product Name : Clinolipid

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 13, 2024

                            Lead Product(s) : Olive

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Baxter Launches Zosyn Premix in US

                            Details : Zosyn is a combination of piperacillin sodium, which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria and tazobactam sodium having activity against bacteria due to its reduced affinity to penicil...

                            Product Name : Zosyn

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 04, 2023

                            Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Biocon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biocon Biologics’ Partner Receives Approval for Human Insulin for IV Infusion

                            Details : Inpremzia is an approved medicine used to treat people with diabetes who need insulin to keep their blood glucose (sugar) level controlled. It contains the active substance insulin human.

                            Product Name : Inpremzia

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 25, 2022

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Biocon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAK-919

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-1...

                            Details : Baxter BioPharma Solutions will provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021.

                            Product Name : mRNA-1273

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 03, 2021

                            Lead Product(s) : TAK-919

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth